Vijan S, Hwang E W, Hofer T P, Hayward R A
The Veterans Affairs Center for Practice Management and Outcomes Research, Ann Arbor, Michigan 48113-0170, USA.
Am J Med. 2001 Dec 1;111(8):593-601. doi: 10.1016/s0002-9343(01)00977-9.
Recent media reports have advocated the use of colonoscopy for colorectal cancer screening. However, colonoscopy is expensive compared with other screening modalities, such as fecal occult blood testing and flexible sigmoidoscopy. We sought to determine the cost effectiveness of different screening strategies for colorectal cancer at levels of compliance likely to be achieved in clinical practice.
A Markov decision model was used to examine screening strategies, including fecal occult blood testing alone, fecal occult blood testing combined with flexible sigmoidoscopy, flexible sigmoidoscopy alone, and colonoscopy. The timing and frequency of screening was varied to assess optimal screening intervals. Sensitivity analyses were conducted to assess the factors that have the greatest effect on the cost effectiveness of screening.
All strategies are cost effective versus no screening, at less than $20,000 per life-year saved. Direct comparison suggests that the most effective strategies are twice-lifetime colonoscopy and flexible sigmoidoscopy combined with fecal occult blood testing. Assuming perfect compliance, flexible sigmoidoscopy combined with fecal occult blood testing is slightly more effective than twice-lifetime colonoscopy (at ages 50 and 60 years) but is substantially more expensive, with an incremental cost effectiveness of $390,000 per additional life-year saved. However, compliance with primary screening tests and colonoscopic follow-up for polyps affect screening decisions. Colonoscopy at ages 50 and 60 years is the preferred test regardless of compliance with the primary screening test. However, if follow-up colonoscopy for polyps is less than 75%, then even once-lifetime colonoscopy is preferred over most combinations of flexible sigmoidoscopy and fecal occult blood testing. Costs of colonoscopy and proportion of cancer arising from polyps also affect cost effectiveness.
Colonoscopic screening for colorectal cancer appears preferable to current screening recommendations. Screening recommendations should be tailored to the compliance levels achievable in different practice settings.
近期媒体报道提倡使用结肠镜检查进行结直肠癌筛查。然而,与其他筛查方式相比,如粪便潜血试验和乙状结肠镜检查,结肠镜检查费用较高。我们试图确定在临床实践中可能达到的依从性水平下,不同结直肠癌筛查策略的成本效益。
采用马尔可夫决策模型来研究筛查策略,包括单独粪便潜血试验、粪便潜血试验联合乙状结肠镜检查、单独乙状结肠镜检查和结肠镜检查。改变筛查的时间和频率以评估最佳筛查间隔。进行敏感性分析以评估对筛查成本效益影响最大的因素。
与不进行筛查相比,所有策略均具有成本效益,每挽救一个生命年的成本低于20,000美元。直接比较表明,最有效的策略是一生两次结肠镜检查以及乙状结肠镜检查联合粪便潜血试验。假设完全依从,乙状结肠镜检查联合粪便潜血试验比一生两次结肠镜检查(在50岁和60岁时)略有效,但成本高得多,每多挽救一个生命年的增量成本效益为390,000美元。然而,对息肉进行初次筛查试验和结肠镜随访的依从性会影响筛查决策。无论对初次筛查试验的依从性如何,50岁和60岁时进行结肠镜检查是首选检查。但是,如果对息肉的随访结肠镜检查低于75%,那么即使是一生一次的结肠镜检查也比大多数乙状结肠镜检查和粪便潜血试验的组合更可取。结肠镜检查的成本以及息肉引发癌症的比例也会影响成本效益。
结直肠癌的结肠镜筛查似乎优于当前的筛查建议。筛查建议应根据不同实践环境中可达到的依从性水平进行调整。